Skip to main content

Table.3 Results of the regression analyses

From: Variables affecting pricing of orphan drugs: the Italian case

  Dependent variable: Log cost
(1) (2) (3) (4) (5) (6)
Prevalence − 0.582** (− 1.122, − 0.041)    − 0.526* (− 1.101, 0.049) 0.829* (− 0.073, 1.731) 1.197** (0.185, 2.210)
RCT   − 0.176 (− 0.739, 0.387)   0.141 (− 0.466, 0.748) 1.029*** (0.301, 1.758) 0.779* (− 0.002, 1.561)
ASMR    − 0.338** (− 0.665, − 0.011) − 0.287 (− 0.625, 0.052) − 0.225 (− 0.530, 0.080) − 0.203 (− 0.533, 0.127)
ATC l       0.091 (− 0.685, 0.867)
Class H of eligibility       − 0.205 (− 0.955, 0.545)
2015       1.468** (0.341, 2.595)
2016       0.908 (− 0.187, 2.004)
2017       1.376*** (0.399, 2.354)
2018       1.110** (0.097, 2.124)
2019       0.888 (− 0.160, 1.937)
Prevalence * RCT      − 2.016*** (− 3.118, − 0.915) − 2.187*** (− 3.338, − 1.037)
Constant 11.554*** (11.168, 11.939) 11.430*** (10.976, 11.884) 12.582*** (11.277, 13.886) 12.653*** (11.260, 14.047) 11.936*** (10.629, 13.244) 10.885*** (9.236, 12.534)
Observations 63 60 55 52 52 52
R2 0.068 0.006 0.072 0.123 0.312 0.449
  1. ASMR Amélioration du Service Médical Rendu, ATC Anatomical Therapeutic Chemical (Classification), Log cost Logarithmic transformation of annual treatmente cost, RCT Randomized Clinical Trial
  2. *p < 0.1; **p < 0.05; ***p < 0.01